Bank of America set a CHF 104 price objective on Novartis (VTX:NOVN) in a research report report published on Friday, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.

Other equities research analysts also recently issued reports about the company. Deutsche Bank set a CHF 90 price objective on Novartis and gave the company a neutral rating in a report on Monday, September 9th. Morgan Stanley set a CHF 83 price objective on Novartis and gave the company a sell rating in a report on Thursday, May 30th. HSBC set a CHF 88 price objective on Novartis and gave the company a neutral rating in a report on Monday, July 22nd. Jefferies Financial Group set a CHF 100 price objective on Novartis and gave the company a buy rating in a report on Friday, August 30th. Finally, Goldman Sachs Group set a CHF 105 price objective on Novartis and gave the company a buy rating in a report on Friday, August 30th. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of CHF 90.85.

Novartis has a 1 year low of CHF 72.45 and a 1 year high of CHF 88.30.

About Novartis

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Further Reading: What is an overbought condition?

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.